Elleacnelle combines cyproterone acetate and ethinylestradiol to help manage androgen related acne, oily skin, and unwanted hair growth. Each tablet contains 2mg cyproterone acetate and 35mcg ethinylestradiol.
FormatTablets
Concentration2mg Cyproterone Acetate + 35mcg Ethinylestradiol per tablet
Package Selected: Single Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Elleacnelle is a combined hormonal tablet formulation delivering Cyproterone Acetate 2000mcg and Ethinylestradiol 35mcg in a fixed ratio dual compound presentation. Combining an antiandrogen with a synthetic estrogen in a single tablet format that has been clinically referenced in dermatological and endocrine research contexts examining combined androgen suppression and estrogen activity. The 4 pack format supplies a structured multi cycle research quantity designed for extended hormonal modulation protocols requiring consistent compound availability across multiple administration periods.
Cyproterone Acetate is a steroidal antiandrogen and progestogen with a well documented pharmaceutical history spanning several decades of clinical application. Its primary mechanism operates through competitive androgen receptor antagonism, blocking dihydrotestosterone and testosterone from binding androgen receptors in target tissue, reducing androgenic stimulation in skin, hair follicles, and other androgen sensitive tissues. Cyproterone Acetate additionally carries progestogenic activity through progesterone receptor binding, producing gonadotropin suppression through negative feedback on the HPG axis. Reducing endogenous LH and FSH secretion and consequently lowering endogenous androgen production alongside its direct receptor blocking activity. This dual mechanism of peripheral androgen receptor blockade and central gonadotropin suppression makes Cyproterone Acetate a frequently studied reference compound in androgen dependent pathway research examining both receptor level and production level androgen regulation.
Ethinylestradiol is a synthetic estrogen with high oral bioavailability; the most widely used synthetic estrogen in pharmaceutical research due to its resistance to first pass hepatic metabolism that limits native estradiol’s oral activity. In this combination formulation, Ethinylestradiol’s estrogenic activity complements Cyproterone Acetate’s antiandrogen and gonadotropin suppressing effects. The combined estrogen and antiandrogen profile producing a well characterized hormonal research environment that has been studied in androgen excess, sebaceous gland activity, and combined sex hormone modulation research contexts. The fixed ratio combination of both compounds in a single tablet supports consistent dual compound administration research without separate dosing of individual components.
Elleacnelle is stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all products we carry, and Elleacnelle meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside androgen receptor modulators and hormonal regulation compounds in comparative sex hormone pathway studies. Browse CSD’s full PCT and hormone research range for complete sourcing.
Elleacnelle is a combined hormonal tablet containing 2mg (2,000mcg) of cyproterone acetate and 35mcg of ethinylestradiol per tablet. Cyproterone acetate is a steroidal antiandrogen with progestogenic activity, while ethinylestradiol is a synthetic estrogen. This 4 pack format contains four 21 tablet packs for 84 tablets total.
Elleacnelle is used in women of reproductive age for moderate to severe acne associated with androgen sensitivity, with or without oily skin, and for excessive hair growth or hirsutism. Official prescribing information specifies that acne treatment with this combination should generally be considered after suitable topical treatments or systemic antibiotics have failed and when hormonal contraceptive treatment is considered appropriate.
Cyproterone acetate blocks androgen receptor activity and also provides progestogenic effects that contribute to suppression of gonadotropin signalling. This reduces androgen related stimulation of tissues such as sebaceous glands and hair follicles. Ethinylestradiol provides estrogenic activity and complements the hormonal suppression produced by cyproterone acetate. Together, the two compounds reduce androgen related activity while also suppressing ovulation.
Yes. The cyproterone acetate and ethinylestradiol combination has contraceptive activity and suppresses ovulation. However, official product information positions Elleacnelle primarily for androgen sensitive acne and hirsutism and states that it should only be prescribed when the clinician also considers hormonal contraception appropriate. It should not be combined with another hormonal contraceptive.
Elleacnelle carries clinically important risks associated with combined estrogen progestogen therapy, particularly venous and arterial thromboembolism. It is contraindicated in several situations involving previous blood clots, certain cardiovascular conditions, migraine with visual symptoms, significant liver disease, certain hormone dependent cancers, unexplained vaginal bleeding, and pregnancy. Medical history and individual thrombotic risk should be assessed by an appropriate healthcare professional before treatment.
